<p>Eledon Pharmaceuticals, Inc.（纳斯达克代码：ELDN - 获取免费报告）在三月份的空头头寸显著增长。截至 3 月 13 日，空头头寸总计为 8,417,915 股，比 2 月 26 日的 6,458,931 股增长了 30.3%。该公司约有 12.7% 的股票被做空。根据平均每日交易量 1,292,590 股，目前的空头头寸比率为 6.5 天。</p>
<p>获取 <strong>Eledon Pharmaceuticals</strong> 的提醒：</p>
<h2>Eledon Pharmaceuticals 股票表现</h2>
<p>在周五的交易中，ELDN 股票下跌 0.13 美元，报 2.83 美元。该公司交易了 864,502 股，较其平均交易量 1,556,412 股有所减少。该公司的 50 日简单移动平均线为 2.44 美元，200 日简单移动平均线为 2.35 美元。Eledon Pharmaceuticals 的 12 个月低点为 1.35 美元，12 个月高点为 4.60 美元。该公司的市值为 2.1466 亿美元，市盈率为-5.44，贝塔值为 0.84。</p>
<p>Eledon Pharmaceuticals（纳斯达克代码：ELDN - 获取免费报告）最近于 3 月 19 日星期四发布了季度财报。该公司报告每股收益为（0.10 美元），超出市场共识预期的（0.20 美元）0.10 美元。分析师平均预测 Eledon Pharmaceuticals 在当前财年将发布每股收益为-0.81 美元。</p>
<h2>分析师评级升级与降级</h2>
<p>另外，Weiss Ratings 在 12 月 29 日的报告中重申了对 Eledon Pharmaceuticals 股票的 “卖出（d-）” 评级。三位分析师给予该股票买入评级，一位给予持有评级，一位给予卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “持有”，平均目标价为 9.67 美元。</p>
<p><strong>阅读我们关于 ELDN 的最新股票报告</strong></p>
<h2>Eledon Pharmaceuticals 的机构交易</h2>
<p>几家对冲基金和其他机构投资者最近调整了对 ELDN 的持股。洛克菲勒资本管理公司在第四季度将其在 Eledon Pharmaceuticals 的持股增加了 95.5%。洛克菲勒资本管理公司现在拥有 71,666 股该公司的股票，价值 108,000 美元，此前在上个季度购买了额外的 35,000 股。Kera Capital Partners Inc.在第四季度将其在 Eledon Pharmaceuticals 的持股增加了 54.3%。Kera Capital Partners Inc.现在拥有 39,770 股该公司的股票，价值 60,000 美元，此前在上个季度收购了额外的 14,000 股。Virtu Financial LLC 在第四季度获得了 Eledon Pharmaceuticals 的新头寸，价值 39,000 美元。XTX Topco Ltd 在第四季度将其在 Eledon Pharmaceuticals 的持股增加了 867.1%。XTX Topco Ltd 现在拥有 124,247 股该公司的股票，价值 188,000 美元，此前在上个季度购买了额外的 111,399 股。最后，Zimmer Partners LP 在第四季度将其在 Eledon Pharmaceuticals 的持股增加了 30.6%。Zimmer Partners LP 现在拥有 2,384,228 股该公司的股票，价值 3,600,000 美元，此前在上个季度购买了额外的 559,228 股。目前 56.77% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>关于 Eledon Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Eledon Pharmaceuticals, Inc.（纳斯达克代码：ELDN）是一家临床阶段的生物制药公司，专注于发现和开发针对平滑肌功能障碍疾病的治疗方法。该公司利用专有的离子通道调节平台，识别和优化小分子化合物，以恢复或抑制平滑肌活动，旨在解决胃肠、肝脏和心血管疾病。</p>
<p>Eledon 的产品管线包括多个针对高未满足需求指征的临床前和早期临床项目。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Eledon Pharmaceuticals</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Eledon Pharmaceuticals 吗？</h2>
<p>在你考虑 Eledon Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Eledon Pharmaceuticals 并不在名单上。</p>
<p>虽然 Eledon Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得投资。</p>
<p>查看这五只股票</p>

ELDN

2 倍做多纳斯达克生物技术 ETF - ProShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>Eledon Pharmaceuticals, Inc.（纳斯达克代码：ELDN）在三月份的空头头寸增加了 30.3%，总计达到 8,417,915 股。这大约占公司股票的 12.7%，根据平均每日交易量 1,292,590 股计算，空头头寸比率为 6.5 天。该股票交易价格下跌至$2.83，市值为 2.1466 亿美元。分析师对 ELDN 的共识评级为 “持有”，平均目标价格为$9.67。机构投资者持有 56.77% 的股份，反映出对该公司的显著兴趣</p>

<p>Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) saw a significant growth in short interest in March. As of March 13th, there was short interest totaling 8,417,915 shares, a growth of 30.3% from the February 26th total of 6,458,931 shares. Approximately 12.7% of the company's stock are short sold. Based on an average daily volume of 1,292,590 shares, the short-interest ratio is currently 6.5 days.</p>
<div class="lb-trans"><p>Eledon Pharmaceuticals, Inc.（纳斯达克代码：ELDN - 获取免费报告）在三月份的空头头寸显著增长。截至 3 月 13 日，空头头寸总计为 8,417,915 股，比 2 月 26 日的 6,458,931 股增长了 30.3%。该公司约有 12.7% 的股票被做空。根据平均每日交易量 1,292,590 股，目前的空头头寸比率为 6.5 天。</p>
</div><p>Get <strong>Eledon Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Eledon Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Eledon Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Eledon Pharmaceuticals 股票表现</h2>
</div><p>Shares of ELDN stock traded down $0.13 during trading on Friday, hitting $2.83. 864,502 shares of the company were exchanged, compared to its average volume of 1,556,412. The business's 50-day simple moving average is $2.44 and its 200 day simple moving average is $2.35. Eledon Pharmaceuticals has a twelve month low of $1.35 and a twelve month high of $4.60. The firm has a market capitalization of $214.66 million, a price-to-earnings ratio of -5.44 and a beta of 0.84.</p>
<div class="lb-trans"><p>在周五的交易中，ELDN 股票下跌 0.13 美元，报 2.83 美元。该公司交易了 864,502 股，较其平均交易量 1,556,412 股有所减少。该公司的 50 日简单移动平均线为 2.44 美元，200 日简单移动平均线为 2.35 美元。Eledon Pharmaceuticals 的 12 个月低点为 1.35 美元，12 个月高点为 4.60 美元。该公司的市值为 2.1466 亿美元，市盈率为-5.44，贝塔值为 0.84。</p>
</div><p>Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last released its quarterly earnings data on Thursday, March 19th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.10. On average, equities analysts forecast that Eledon Pharmaceuticals will post -0.81 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Eledon Pharmaceuticals（纳斯达克代码：ELDN - 获取免费报告）最近于 3 月 19 日星期四发布了季度财报。该公司报告每股收益为（0.10 美元），超出市场共识预期的（0.20 美元）0.10 美元。分析师平均预测 Eledon Pharmaceuticals 在当前财年将发布每股收益为-0.81 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级升级与降级</h2>
</div><p>Separately, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Eledon Pharmaceuticals in a report on Monday, December 29th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of &#34;Hold&#34; and an average price target of $9.67.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 12 月 29 日的报告中重申了对 Eledon Pharmaceuticals 股票的 “卖出（d-）” 评级。三位分析师给予该股票买入评级，一位给予持有评级，一位给予卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “持有”，平均目标价为 9.67 美元。</p>
</div><p><strong>Read Our Latest Stock Report on ELDN</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 ELDN 的最新股票报告</strong></p>
</div><h2>Institutional Trading of Eledon Pharmaceuticals</h2>
<div class="lb-trans"><h2>Eledon Pharmaceuticals 的机构交易</h2>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of ELDN. Rockefeller Capital Management L.P. boosted its position in Eledon Pharmaceuticals by 95.5% during the fourth quarter. Rockefeller Capital Management L.P. now owns 71,666 shares of the company's stock valued at $108,000 after purchasing an additional 35,000 shares during the last quarter. Kera Capital Partners Inc. grew its position in Eledon Pharmaceuticals by 54.3% in the fourth quarter. Kera Capital Partners Inc. now owns 39,770 shares of the company's stock worth $60,000 after acquiring an additional 14,000 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Eledon Pharmaceuticals during the 4th quarter worth $39,000. XTX Topco Ltd increased its stake in shares of Eledon Pharmaceuticals by 867.1% during the 4th quarter. XTX Topco Ltd now owns 124,247 shares of the company's stock worth $188,000 after purchasing an additional 111,399 shares during the last quarter. Finally, Zimmer Partners LP raised its holdings in shares of Eledon Pharmaceuticals by 30.6% during the 4th quarter. Zimmer Partners LP now owns 2,384,228 shares of the company's stock valued at $3,600,000 after purchasing an additional 559,228 shares in the last quarter. 56.77% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近调整了对 ELDN 的持股。洛克菲勒资本管理公司在第四季度将其在 Eledon Pharmaceuticals 的持股增加了 95.5%。洛克菲勒资本管理公司现在拥有 71,666 股该公司的股票，价值 108,000 美元，此前在上个季度购买了额外的 35,000 股。Kera Capital Partners Inc.在第四季度将其在 Eledon Pharmaceuticals 的持股增加了 54.3%。Kera Capital Partners Inc.现在拥有 39,770 股该公司的股票，价值 60,000 美元，此前在上个季度收购了额外的 14,000 股。Virtu Financial LLC 在第四季度获得了 Eledon Pharmaceuticals 的新头寸，价值 39,000 美元。XTX Topco Ltd 在第四季度将其在 Eledon Pharmaceuticals 的持股增加了 867.1%。XTX Topco Ltd 现在拥有 124,247 股该公司的股票，价值 188,000 美元，此前在上个季度购买了额外的 111,399 股。最后，Zimmer Partners LP 在第四季度将其在 Eledon Pharmaceuticals 的持股增加了 30.6%。Zimmer Partners LP 现在拥有 2,384,228 股该公司的股票，价值 3,600,000 美元，此前在上个季度购买了额外的 559,228 股。目前 56.77% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>About Eledon Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Eledon Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Eledon Pharmaceuticals, Inc NASDAQ: ELDN is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for diseases characterized by smooth muscle dysfunction. The company leverages a proprietary ion-channel modulation platform to identify and optimize small-molecule compounds that can either restore or inhibit smooth muscle activity, with the goal of addressing gastrointestinal, hepatic and cardiovascular disorders.</p>
<div class="lb-trans"><p>Eledon Pharmaceuticals, Inc.（纳斯达克代码：ELDN）是一家临床阶段的生物制药公司，专注于发现和开发针对平滑肌功能障碍疾病的治疗方法。该公司利用专有的离子通道调节平台，识别和优化小分子化合物，以恢复或抑制平滑肌活动，旨在解决胃肠、肝脏和心血管疾病。</p>
</div><p>Eledon's pipeline comprises several preclinical and early-phase clinical programs targeting high-unmet-need indications.</p>
<div class="lb-trans"><p>Eledon 的产品管线包括多个针对高未满足需求指征的临床前和早期临床项目。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Eledon Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Eledon Pharmaceuticals</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eledon Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Eledon Pharmaceuticals 吗？</h2>
</div><p>Before you consider Eledon Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Eledon Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eledon Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Eledon Pharmaceuticals 并不在名单上。</p>
</div><p>While Eledon Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Eledon Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得投资。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Eledon Pharmaceuticals, Inc.（NASDAQ:ELDN）的空头头寸增加了 30.3%